SOURCE: BioMedReports


October 09, 2009 10:21 ET

Interview With Hemispherx Biopharma's Chief Executive Officer, Dr. William A. Carter

LOS ANGELES, CA--(Marketwire - October 9, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with Hemispherx Biopharma's (NYSE Amex: HEB) Chief Executive Officer, Dr. William A. Carter.

The investment community has been asking for an update on the company's application with the FDA for the use of Ampligen as a treatment for Chronic Fatigue Syndrome (CFS) and BioMedReports has it.

Has the company been in touch with the FDA about the long delayed decision?

What are the company's plans for new clinical trials of its Alferon LDO (Low Dose Oral)?

What are the implications of the new data released by Stanford University regarding the Immuno-Potential of Hemispherx's Ampligen?

These and many more in-depth details can be heard on the special report interview which is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Contact:
    M. Davila
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556